Titre : Interféron alpha

Interféron alpha : Questions médicales fréquentes

Termes MeSH sélectionnés :

Interferon-alpha
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Interféron alpha : Questions médicales les plus fréquentes", "headline": "Interféron alpha : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Interféron alpha : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-14", "dateModified": "2025-04-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Interféron alpha" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Interféron de type I", "url": "https://questionsmedicales.fr/mesh/D007370", "about": { "@type": "MedicalCondition", "name": "Interféron de type I", "code": { "@type": "MedicalCode", "code": "D007370", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.440.890" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Interféron alpha-2", "alternateName": "Interferon alpha-2", "url": "https://questionsmedicales.fr/mesh/D000077190", "about": { "@type": "MedicalCondition", "name": "Interféron alpha-2", "code": { "@type": "MedicalCode", "code": "D000077190", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.440.890.250.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Interféron alpha", "alternateName": "Interferon-alpha", "code": { "@type": "MedicalCode", "code": "D016898", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Tim Maiwald", "url": "https://questionsmedicales.fr/author/Tim%20Maiwald", "affiliation": { "@type": "Organization", "name": "Institute for Physics, University of Freiburg, Germany." } }, { "@type": "Person", "name": "Marcel Schilling", "url": "https://questionsmedicales.fr/author/Marcel%20Schilling", "affiliation": { "@type": "Organization", "name": "Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany." } }, { "@type": "Person", "name": "Melissa Teusel", "url": "https://questionsmedicales.fr/author/Melissa%20Teusel", "affiliation": { "@type": "Organization", "name": "Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany." } }, { "@type": "Person", "name": "Georg Damm", "url": "https://questionsmedicales.fr/author/Georg%20Damm", "affiliation": { "@type": "Organization", "name": "Department of Hepatobiliary Surgery and Visceral Transplantation, University of Leipzig, Leipzig, Germany and Department of General-, Visceral- and Transplantation Surgery, Charité University Medicine Berlin, Berlin, Germany." } }, { "@type": "Person", "name": "Daniel Seehofer", "url": "https://questionsmedicales.fr/author/Daniel%20Seehofer", "affiliation": { "@type": "Organization", "name": "Department of Hepatobiliary Surgery and Visceral Transplantation, University of Leipzig, Leipzig, Germany and Department of General-, Visceral- and Transplantation Surgery, Charité University Medicine Berlin, Berlin, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection.", "datePublished": "2023-10-30", "url": "https://questionsmedicales.fr/article/37902466", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2340/actadv.v103.10306" } }, { "@type": "ScholarlyArticle", "name": "Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19.", "datePublished": "2023-03-16", "url": "https://questionsmedicales.fr/article/36927455", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13054-023-04388-8" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of topical 5-fluorouracil in conjunctival intraepithelial neoplasia refractory to interferon alpha-2b.", "datePublished": "2022-09-21", "url": "https://questionsmedicales.fr/article/36131486", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/10781552221125763" } }, { "@type": "ScholarlyArticle", "name": "The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B.", "datePublished": "2022-07-20", "url": "https://questionsmedicales.fr/article/35854256", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12887-022-03482-0" } }, { "@type": "ScholarlyArticle", "name": "Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha.", "datePublished": "2023-05-22", "url": "https://questionsmedicales.fr/article/37217910", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12902-023-01371-w" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Interférons", "item": "https://questionsmedicales.fr/mesh/D007372" }, { "@type": "ListItem", "position": 6, "name": "Interféron de type I", "item": "https://questionsmedicales.fr/mesh/D007370" }, { "@type": "ListItem", "position": 7, "name": "Interféron alpha", "item": "https://questionsmedicales.fr/mesh/D016898" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Interféron alpha - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Interféron alpha", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Interféron alpha", "description": "Comment diagnostiquer une infection virale nécessitant l'interféron alpha ?\nQuels tests sont utilisés pour évaluer l'efficacité de l'interféron alpha ?\nQuels marqueurs sont surveillés lors d'un traitement par interféron alpha ?\nComment évaluer les effets secondaires de l'interféron alpha ?\nQuels symptômes indiquent un besoin d'interféron alpha ?", "url": "https://questionsmedicales.fr/mesh/D016898?mesh_terms=Interferon-alpha&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Interféron alpha", "description": "Quels sont les effets secondaires courants de l'interféron alpha ?\nComment l'interféron alpha affecte-t-il le système immunitaire ?\nQuels symptômes peuvent survenir après une injection d'interféron alpha ?\nL'interféron alpha peut-il provoquer des troubles psychologiques ?\nQuels signes indiquent une réaction allergique à l'interféron alpha ?", "url": "https://questionsmedicales.fr/mesh/D016898?mesh_terms=Interferon-alpha&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Interféron alpha", "description": "L'interféron alpha peut-il prévenir des infections ?\nQuelles mesures préventives sont recommandées lors d'un traitement ?\nDes vaccins sont-ils compatibles avec l'interféron alpha ?\nComment minimiser les effets secondaires pendant le traitement ?\nY a-t-il des restrictions alimentaires pendant le traitement ?", "url": "https://questionsmedicales.fr/mesh/D016898?mesh_terms=Interferon-alpha&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Interféron alpha", "description": "Comment l'interféron alpha est-il administré ?\nQuels types de cancers sont traités avec l'interféron alpha ?\nL'interféron alpha est-il utilisé pour des infections chroniques ?\nQuels sont les protocoles de traitement avec l'interféron alpha ?\nPeut-on combiner l'interféron alpha avec d'autres traitements ?", "url": "https://questionsmedicales.fr/mesh/D016898?mesh_terms=Interferon-alpha&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Interféron alpha", "description": "Quelles complications peuvent survenir avec l'interféron alpha ?\nComment gérer les complications liées à l'interféron alpha ?\nL'interféron alpha peut-il causer des maladies auto-immunes ?\nQuels signes indiquent une complication grave ?\nLes complications sont-elles réversibles après l'arrêt du traitement ?", "url": "https://questionsmedicales.fr/mesh/D016898?mesh_terms=Interferon-alpha&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Interféron alpha", "description": "Quels facteurs augmentent le risque d'effets secondaires ?\nLes femmes enceintes peuvent-elles utiliser l'interféron alpha ?\nY a-t-il des interactions médicamenteuses à surveiller ?\nLes antécédents de dépression augmentent-ils les risques ?\nLes patients atteints de maladies hépatiques doivent-ils être prudents ?", "url": "https://questionsmedicales.fr/mesh/D016898?mesh_terms=Interferon-alpha&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection virale nécessitant l'interféron alpha ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic repose sur des tests sanguins, des cultures virales et des symptômes cliniques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'efficacité de l'interféron alpha ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de charge virale et des biopsies peuvent être effectués pour évaluer l'efficacité." } }, { "@type": "Question", "name": "Quels marqueurs sont surveillés lors d'un traitement par interféron alpha ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs hépatiques, la numération globulaire et les anticorps spécifiques sont surveillés." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires de l'interféron alpha ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires sont évalués par des examens cliniques et des questionnaires de qualité de vie." } }, { "@type": "Question", "name": "Quels symptômes indiquent un besoin d'interféron alpha ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fièvre, la fatigue et des douleurs peuvent indiquer un besoin d'interféron." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de l'interféron alpha ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent fatigue, fièvre, douleurs musculaires et dépression." } }, { "@type": "Question", "name": "Comment l'interféron alpha affecte-t-il le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Il stimule le système immunitaire, augmentant la réponse contre les infections et les tumeurs." } }, { "@type": "Question", "name": "Quels symptômes peuvent survenir après une injection d'interféron alpha ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des frissons, des maux de tête et des douleurs au site d'injection peuvent survenir." } }, { "@type": "Question", "name": "L'interféron alpha peut-il provoquer des troubles psychologiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut entraîner des troubles comme l'anxiété et la dépression chez certains patients." } }, { "@type": "Question", "name": "Quels signes indiquent une réaction allergique à l'interféron alpha ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées, des démangeaisons ou un gonflement peuvent indiquer une allergie." } }, { "@type": "Question", "name": "L'interféron alpha peut-il prévenir des infections ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'est pas utilisé comme prévention, mais peut réduire la gravité des infections virales." } }, { "@type": "Question", "name": "Quelles mesures préventives sont recommandées lors d'un traitement ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les infections, se laver les mains et suivre un régime équilibré sont recommandés." } }, { "@type": "Question", "name": "Des vaccins sont-ils compatibles avec l'interféron alpha ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Certains vaccins peuvent être administrés, mais il est important de consulter un médecin." } }, { "@type": "Question", "name": "Comment minimiser les effets secondaires pendant le traitement ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Rester hydraté, se reposer et suivre les conseils médicaux peuvent aider à minimiser les effets." } }, { "@type": "Question", "name": "Y a-t-il des restrictions alimentaires pendant le traitement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Aucune restriction alimentaire spécifique, mais une alimentation équilibrée est conseillée." } }, { "@type": "Question", "name": "Comment l'interféron alpha est-il administré ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il est généralement administré par injection sous-cutanée ou intramusculaire." } }, { "@type": "Question", "name": "Quels types de cancers sont traités avec l'interféron alpha ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il est utilisé pour traiter des cancers comme le mélanome et le cancer du rein." } }, { "@type": "Question", "name": "L'interféron alpha est-il utilisé pour des infections chroniques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est utilisé pour traiter des infections chroniques comme l'hépatite C." } }, { "@type": "Question", "name": "Quels sont les protocoles de traitement avec l'interféron alpha ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les protocoles varient selon la maladie, mais incluent souvent des doses régulières sur plusieurs mois." } }, { "@type": "Question", "name": "Peut-on combiner l'interféron alpha avec d'autres traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être combiné avec d'autres thérapies comme la chimiothérapie ou les antiviraux." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'interféron alpha ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des troubles hématologiques, des problèmes hépatiques et des dépressions peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer les complications liées à l'interféron alpha ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut un suivi médical régulier et des ajustements de traitement si nécessaire." } }, { "@type": "Question", "name": "L'interféron alpha peut-il causer des maladies auto-immunes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Il existe un risque accru de maladies auto-immunes chez certains patients sous interféron alpha." } }, { "@type": "Question", "name": "Quels signes indiquent une complication grave ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des saignements, des douleurs abdominales ou des changements mentaux doivent être signalés." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles après l'arrêt du traitement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles, mais d'autres peuvent nécessiter un traitement supplémentaire." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'effets secondaires ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé, des antécédents de maladies psychiatriques et d'autres traitements augmentent le risque." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles utiliser l'interféron alpha ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation pendant la grossesse est généralement déconseillée en raison des risques potentiels." } }, { "@type": "Question", "name": "Y a-t-il des interactions médicamenteuses à surveiller ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des interactions avec des médicaments immunosuppresseurs ou des anticoagulants doivent être surveillées." } }, { "@type": "Question", "name": "Les antécédents de dépression augmentent-ils les risques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents de dépression peuvent augmenter le risque de troubles psychologiques sous interféron." } }, { "@type": "Question", "name": "Les patients atteints de maladies hépatiques doivent-ils être prudents ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des maladies hépatiques doivent être étroitement surveillés lors du traitement." } } ] } ] }

Sources (5649 au total)

Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19.

The use of glucocorticoids has given contradictory results for treating acute respiratory distress syndrome (ARDS). The use of intravenous Interferon beta (IFN β) for the treatment of ARDS was recentl... We first sequenced the genes encoding the IFN α/β receptor of the patients, who participated in the INTEREST study (ClinicalTrials.gov Identifier: NCT02622724 , November 24, 2015) in which the patient... We found a novel disease association of a SNP rs9984273, which is situated in the interferon α/β receptor subunit 2 (IFNAR2) gene in an area corresponding to a binding motif of the glucocorticoid rece... The distribution of this SNP within clinical study arms may explain the contradictory results of multiple ARDS studies and outcomes in COVID-19 concerning type I IFN signaling and glucocorticoids....

Efficacy and safety of topical 5-fluorouracil in conjunctival intraepithelial neoplasia refractory to interferon alpha-2b.

To report the efficacy and safety of 5-fluorouracil as the second line of treatment for two cases of conjunctival intraepithelial neoplasia refractive to topical interferon alpha-2b.... In the first case, a 77-year-old woman was evaluated because of a fleshy vascularized lesion in the temporal conjunctiva on her right eye with leukoplakia of the corneal epithelium from 10- to 5-o'clo... In the absence of efficacy, the treatment was then changed to topical 5-fluorouracil (1%), 4 times/day for 7 days with a time-lapse of 21 days off, which constitutes a course. Two and four courses of ... The treatment with 5-fluorouracil is a good option as the second line of treatment for conjunctival intraepithelial neoplasia who are low-responders to interferon alpha-2b, with fewer side effects tha...

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B.

Pegylated interferon alpha-2a (peg-IFN α-2a) and entecavir (ETV) are both recommended as the first-line antiviral drugs for chronic hepatitis B (CHB) at present. We aimed to compare the efficacy and s... We retrospectively selected 70 treatment-naïve children and adolescents with CHB who received peg-IFN α-2a(n = 26) or ETV(n = 44) as initial therapy and completed 48-week follow-up for data analysis. ... We found that initial peg-IFN therapy results in higher rates of hepatitis B surface antigen (HBsAg) serological response (SR) but lower rates of virological and biochemical response rates compared to... comparing to ETV, peg-IFN was superior in achieving HBsAg and HBeAg SR; higher baseline IL-18 levels were independently associated with HBeAg SR in this study of children and adolescents with CHB....

Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha.

Thyroid disorders (TD) is a common complication of pegylated-interferon alpha (Peg-IFNα) therapy. Few studies have investigated the relationship between TD and the efficacy of interferon therapy for c... In this retrospective study, the clinical data of 146 patients with CHB receiving Peg-IFNα therapy were collected and analyzed.... During the course of Peg-IFNα therapy, positive conversion of thyroid autoantibodies and TD occurred in 7.3% (85/1158) and 8.8% (105/1187) patients, respectively, and was diagnosed more often in women... TD are not an absolute contraindication for interferon therapy; however, patients should be monitored closely during interferon therapy. In pursuit of functional cure, a balance between efficacy and s...

Thrombotic thrombocytopenic purpura in a patient on long-term alpha-interferon therapy for essential thrombocythemia: a case report.

Thrombotic thrombocytopenic purpura (TTP) is rare and severe thrombotic microangiopathy characterized by thrombocytopenia, hemolytic anemia, and renal dysfunction. In contrast, essential thrombocythem... A 31-year-old Chinese female who was previously diagnosed with ET presented with anemia and renal dysfunction. The patient had been on long-term treatment with hydroxyurea, aspirin, and alpha interfer... We report a case of an ET patient complicated with TTP that was possibly due to INF-α, highlighting the potential complications associated with long-term ET therapy. The case also highlights the impor...

Middle East respiratory syndrome coronavirus ORF4b protein inhibits TLR7- and TLR9-dependent alpha interferon induction.

The Toll-like receptor (TLR)7- and TLR9-dependent signalling cascade is responsible for production of a large amount of alpha interferon by plasmacytoid dendritic cells upon viral infection. Here, we ...

The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment.

Hepatitis B surface antigen (HBsAg) loss is regarded as a pivotal criterion for assessing functional cure in patients diagnosed chronic hepatitis B (CHB). We conducted the research to investigate the ... This retrospective analysis confirmed 295 patients who attained HBsAg loss through combination therapy involving nucleos(t)ide analogues (NAs) and pegylated interferon alpha (peg-IFNα). Employing Kapl... HBsAg seroreversion was observed in 45 patients during follow-up periods, with a lower recurrence risk in patients with HBsAg seroconversion at the end of peg-IFNα therapy (EOT) (10.3% vs 37.3% at 96-... HBsAg seroconversion was beneficial for sustaining functional cure in patients treated with peg-IFNα. Continuing consolidation therapy after HBsAg seroconversion also contributed to maintain HBsAg ser...

CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.

Current treatment options for prostate cancer focus on targeting androgen receptor (AR) signaling. Inhibiting effects of AR may activate neuroendocrine differentiation and lineage plasticity pathways,...

Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus.

An increased risk of pregnancy complications is seen in women with systemic lupus erythematosus (SLE), but the specific immunopathological drivers are still unclear. Hallmarks of SLE are granulocyte a... Repeated blood samples were collected during pregnancy in trimesters one, two, and three from 69 women with SLE and 27 healthy pregnant women (HC). Nineteen of the SLE women were also sampled late pos... Women with SLE had higher LDG proportions and increased IFNα protein levels compared to HC throughout pregnancy, but neither LDG fractions nor IFNα levels differed during pregnancy compared to postpar... Our results suggest that SLE pregnancy results in increased peripheral granulocyte priming, and that higher LDG proportions late in pregnancy are related to shorter pregnancy duration but not to IFNα ...